title: Vulnerability to ventricular fibrillation related to ischaemia: comparison of the acute effects of beta-blockers and calcium antagonists.
abstract: A comparative evaluation of beta-blockers and calcium antagonists as protective agents against ventricular fibrillation related to myocardial ischaemia, was attempted in the pig heart in situ of anaesthetized, open-chest animals, subjected to a temporary complete occlusion of the left anterior descending coronary artery near its origin. This occlusion resulted in fibrillation occurring after a time depending on the vulnerability to the fibrillatory process. As this time to onset of fibrillation does normally not exceed a few minutes, its determination could be achieved repeatedly in the course of an experiment, in the absence and presence of drugs such as beta-blockers and calcium antagonists. When propranolol (0.05 mg/kg, i.v.) and verapamil (0.05 mg/kg, i.v.) abolished tachycardia produced by isoproterenol (0.25 micrograms/kg/min), the triggering of fibrillation was delayed in either case: in animals under atrial pacing at a rate close to the sinus rate on each determination, time to fibrillation was prolonged from about 160 to 400 sec by propranolol and from 160 to 640 sec by verapamil, with a return to control values within 60 min. Under ventricular pacing at a constant high rate (180 beats/min), no change was observed in time to fibrillation after propranolol (0.025 or 0.050 mg/kg), whereas verapamil, in the same conditions and in the same doses, multiplied this time by about 4 and 6, respectively. Consequently, propranolol and verapamil are likely to protect against fibrillation immediately after i.v. injection, but the protection due to propranolol is only indirect and a consequence of bradycardia which tends to increase the polarization of the muscular fibres, whereas verapamil adds to the same influence a direct preventive action by avoiding a cellular calcium overload in these fibres, which is responsible for the depolarization and fluctuations of their membrane potential.
authors.affiliation: Department of Cardiology, Saint Joseph-Saint Luc Hospital Lyon, France.
authors.forename: J F
authors.initials: JF
authors.lastname: Aupetit
authors.forename: Q
authors.initials: Q
authors.lastname: Timour
authors.forename: M
authors.initials: M
authors.lastname: Freysz
authors.forename: J
authors.initials: J
authors.lastname: Loufoua-Moundanga
authors.forename: S
authors.initials: S
authors.lastname: Omar
authors.forename: G
authors.initials: G
authors.lastname: Chevrel
authors.forename: G
authors.initials: G
authors.lastname: Faucon
mesh_terms: D000818:Animals; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007545:Isoproterenol / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy*; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D013552:Swine; D014693:Ventricular Fibrillation / Q000517:prevention & control*; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D011433:Propranolol; D014700:Verapamil; D007545:Isoproterenol